Pectin
Phase 2Small molecule
Pectin is one of 34 small molecule programs targeting Constipation. It is currently in Phase 2.
2
Indications
6
Total Trials
2
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
540 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Aranesp
AmgenPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Uloric
TakedaPreclinical
Lorelco
SanofiPreclinical
Sovaldi
GileadPreclinical
Activase
RochePreclinical
Flomax
SanofiPreclinical
Miochol
BBausch Health Americas, Inc.
Preclinical
Pectin
JJinling Hospital, China
Phase 2
Genotropin
EMD SeronoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Constipation1 trial
Critically Ill Patients1 trial
Chronic Kidney Disease1 trial
Effect of Pectin in Chronic Kidney Disease Patients ( Stage 3 and 4 )
Not yet recruiting·—·Phase 2·NCT06531993·98 enrolled
1 more indication
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pectin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- JJinling Hospital, China